We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
Dana-Farber Cancer Institute
UT Southwestern Medical Center
City of Hope
|Credit Amount:||1.5 Credits|
|Estimated Time for Completion:||90 minutes|
|Cost:||Free of Charge|
The treatment landscape in renal cell carcinoma (RCC) continues to expand, providing more novel targeted, immunotherapeutic, and combination therapy options for patients with advanced disease. A panel of top experts in kidney cancer convened to present the highlights of the most current clinical data on multikinase inhibitors, other targeted therapies, and immune therapies in the upfront setting and in previously treated patients with advanced RCC, and put the clinical implications of these data into perspective to guide optimal application of the latest evidence to practice. Going beyond the standard didactic lectures, Dr. Toni Choueiri, the activity chair and moderator, engages his colleagues in a stimulating, interactive discussion within the framework of real case scenarios discussed throughout the symposium.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of medical and urologic oncologists and other clinicians involved in the care of patients with RCC.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: March 16, 2017 - March 15, 2018
Time to Complete: 90 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.
Toni Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Toni Choueiri, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Bristol-Myers Squibb Company; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Toni Choueiri, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various targeted agents and immunotherapies alone or in combinations for renal cell carcinoma.
Hans Hammers, MD, PhD
UT Southwestern Medical Center
Kidney Cancer Program
Department of Internal Medicine
Division of Hematology and Oncology
Hans Hammers, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company; Eisai Co., Ltd.; Exelixis, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Grant/Research Support from Bristol-Myers Squibb Company; Eisai Co., Ltd.; Exelixis, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Hans Hammers, MD, PhD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various targeted agents and immunotherapies alone or in combinations for renal cell carcinoma.
Sumanta Kumar Pal, MD
Associate Professor, Genitourinary Malignancies
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope
Sumanta Kumar Pal, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Honorarium from Genentech, Inc.
Sumanta Kumar Pal, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various targeted agents and immunotherapies alone or in combinations for renal cell carcinoma.
Vishwanath Sathyanarayanan, MD, DM
Bangalore, Karnataka, India
Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education
Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This educational activity is supported by a medical education grant from Exelixis, Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.
Copyright © 2000-2017, PeerView Press - Medical Education Resource
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.